MA28531B1 - Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 - Google Patents

Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Info

Publication number
MA28531B1
MA28531B1 MA29385A MA29385A MA28531B1 MA 28531 B1 MA28531 B1 MA 28531B1 MA 29385 A MA29385 A MA 29385A MA 29385 A MA29385 A MA 29385A MA 28531 B1 MA28531 B1 MA 28531B1
Authority
MA
Morocco
Prior art keywords
pdea4
pyrazolo
pyridine
inhibitor
composition
Prior art date
Application number
MA29385A
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen Iv
Caroline Mary Cook
Christopher David Edlin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Amyn Pyarali Sayani
Naimisha Trivedi
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28531B1 publication Critical patent/MA28531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
MA29385A 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 MA28531B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
MA28531B1 true MA28531B1 (fr) 2007-04-03

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29385A MA28531B1 (fr) 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Country Status (15)

Country Link
US (2) US20080275078A1 (fr)
EP (2) EP1735314A1 (fr)
JP (2) JP2007529464A (fr)
KR (1) KR20060130744A (fr)
AR (1) AR048175A1 (fr)
AU (1) AU2005223351A1 (fr)
BR (1) BRPI0508843A (fr)
CA (1) CA2559629A1 (fr)
IL (1) IL178011A0 (fr)
MA (1) MA28531B1 (fr)
NO (1) NO20064450L (fr)
PE (1) PE20060078A1 (fr)
RU (1) RU2378274C2 (fr)
TW (1) TW200602051A (fr)
WO (2) WO2005090352A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
EP1735314A1 (fr) * 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
CL2009000250A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
WO2009100169A1 (fr) * 2008-02-06 2009-08-13 Glaxo Group Limited Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
BRPI1006162A2 (pt) 2009-01-13 2019-09-24 Glaxo Group Ltd "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (fr) 2009-03-10 2010-09-16 Glaxo Group Limited Dérivés d'indole comme inhibiteurs de ikk2
EP2408769A1 (fr) 2009-03-17 2012-01-25 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
CN102159191B (zh) * 2009-04-13 2014-04-02 苏鲁·苏布拉马尼·瓦南加穆迪 使用夫西地酸钠制备且加入生物聚合物的医用夫西地酸乳膏及其制备方法
DK2899191T3 (da) 2009-04-30 2017-11-13 Glaxo Group Ltd Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
RS54286B1 (en) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9939529B2 (en) 2012-08-27 2018-04-10 Aktiebolaget Electrolux Robot positioning system
EP2986193B1 (fr) 2013-04-15 2020-07-29 Aktiebolaget Electrolux Dispositif de nettoyage sous vide robotisé avec brosse latérale saillante
JP6217952B2 (ja) 2013-04-15 2017-10-25 アクティエボラゲット エレクトロラックス ロボット真空掃除機
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
CA2923995A1 (fr) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
JP6475707B2 (ja) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
JP6638987B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス 回転側面ブラシの適応速度制御
EP3084539B1 (fr) 2013-12-19 2019-02-20 Aktiebolaget Electrolux Priorisation de zones de nettoyage
JP6750921B2 (ja) 2013-12-19 2020-09-02 アクチエボラゲット エレクトロルックス ロボット掃除機
JP6638988B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス サイドブラシを有し、渦巻きパターンで動くロボットバキュームクリーナ
CN105813528B (zh) 2013-12-19 2019-05-07 伊莱克斯公司 机器人清洁设备的障碍物感测爬行
JP6687286B2 (ja) 2013-12-19 2020-04-22 アクチエボラゲット エレクトロルックス ロボット掃除機およびランドマーク認識方法
EP3084538B1 (fr) 2013-12-19 2017-11-01 Aktiebolaget Electrolux Dispositif de nettoyage robotisé à fonction d'enregistrement de périmètre
JP6336063B2 (ja) 2013-12-20 2018-06-06 アクチエボラゲット エレクトロルックス ダスト容器
WO2015173701A2 (fr) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Compositions pharmaceutiques pour traiter des maladies infecteuses
US10518416B2 (en) 2014-07-10 2019-12-31 Aktiebolaget Electrolux Method for detecting a measurement error in a robotic cleaning device
US10499778B2 (en) 2014-09-08 2019-12-10 Aktiebolaget Electrolux Robotic vacuum cleaner
US10729297B2 (en) 2014-09-08 2020-08-04 Aktiebolaget Electrolux Robotic vacuum cleaner
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
CN106998980B (zh) 2014-12-10 2021-12-17 伊莱克斯公司 使用激光传感器检测地板类型
CN114668335A (zh) 2014-12-12 2022-06-28 伊莱克斯公司 侧刷和机器人吸尘器
KR102339531B1 (ko) 2014-12-16 2021-12-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 경험-기반의 로드맵
JP6532530B2 (ja) 2014-12-16 2019-06-19 アクチエボラゲット エレクトロルックス ロボット掃除機の掃除方法
US11099554B2 (en) 2015-04-17 2021-08-24 Aktiebolaget Electrolux Robotic cleaning device and a method of controlling the robotic cleaning device
EP3344104B1 (fr) 2015-09-03 2020-12-30 Aktiebolaget Electrolux Système de dispositifs de nettoyage robotisés
PL3359541T3 (pl) * 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR102588486B1 (ko) 2016-03-15 2023-10-11 에이비 엘렉트로룩스 로봇 청소 장치 및 로봇 청소 장치에서의 절벽 검출 실시 방법
US11122953B2 (en) 2016-05-11 2021-09-21 Aktiebolaget Electrolux Robotic cleaning device
EP3497100A1 (fr) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Composés chimiques
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7243967B2 (ja) 2017-06-02 2023-03-22 アクチエボラゲット エレクトロルックス ロボット清掃デバイスの前方の表面のレベル差を検出する方法
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111093447B (zh) 2017-09-26 2022-09-02 伊莱克斯公司 机器人清洁设备的移动控制
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2002098878A1 (fr) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines en tant qu'inhibiteurs de la phosphodiesterase 4
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (fr) 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Also Published As

Publication number Publication date
KR20060130744A (ko) 2006-12-19
CA2559629A1 (fr) 2005-09-29
JP2007529464A (ja) 2007-10-25
BRPI0508843A (pt) 2007-08-28
WO2005090354A1 (fr) 2005-09-29
RU2006132684A (ru) 2008-04-27
TW200602051A (en) 2006-01-16
AR048175A1 (es) 2006-04-05
PE20060078A1 (es) 2006-03-10
AU2005223351A1 (en) 2005-09-29
US7709497B2 (en) 2010-05-04
JP2007529486A (ja) 2007-10-25
RU2378274C2 (ru) 2010-01-10
NO20064450L (no) 2006-11-14
US20080275078A1 (en) 2008-11-06
US20070280971A1 (en) 2007-12-06
EP1740590A1 (fr) 2007-01-10
EP1735314A1 (fr) 2006-12-27
IL178011A0 (en) 2006-12-31
WO2005090352A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
MA28531B1 (fr) Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
ZA200508300B (en) RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith
SG103904A1 (en) Colored absorbent article
HK1097269A1 (en) Tricyclic compounds and their use as mglur1 antagonists
HK1101304A1 (en) Bicyclic anthranilamide derivatives useful as insecticides
NO20071364L (no) 6H-[l] benzopyrano[4,3-b]-kinoliner og deres anvendelse som østrogenmidler
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
IL179149A0 (en) Therapeutic compounds: pyridine as scaffold
DK1611131T3 (da) Pyrazolopyridin-derivater
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
DK1814880T3 (da) Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
ATE396724T1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
ATE382261T1 (de) Flüssige formulierung
GB0319874D0 (en) Novel formulation
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
EP1786433A4 (fr) Derives de betulinol utilises en tant qu'agents anti-vih
AU2003268075A1 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2002251140A1 (en) Chemical derivatives and their use as anti-telomerase agent
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
AU2003303678A1 (en) Urea derivatives and their use as anti-inflammatory agents
FR2857363B1 (fr) 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation